Coherus BioSciences News

Express News | Coherus BioSciences Appoints Rita Karachun, Cpa, Cgma to Its Board of Directors

ReutersJun 5 09:00 ET

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Globe NewswireMay 30 09:00 ET

H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12

H.C. Wainwright analyst Douglas Tsao maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 37.

moomoo NewsMay 24 06:32 ET

Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

BenzingaMay 24 06:26 ET

Buy Rating Affirmed for Coherus Biosciences on CHS-114's Promising Clinical Data and Strong Financial Projections

TipRanksMay 24 06:25 ET

Express News | Coherus BioSciences: Chs-114 Shown to Have Acceptable Safety Profile With No Dose-Limiting Toxicities in Heavily Pretreated Patients With Solid Tumors

ReutersMay 23 17:51 ET

Express News | Coherus Presents Preliminary Results From Phase I Dose Escalation Study of Its Anti-Chemokine Receptor 8 (Ccr8) Antibody, Chs-114, at the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

ReutersMay 23 17:51 ET

Coherus Presents Preliminary Results From Phase I Dose Escalation Study of Its Anti-chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago.

GlobeNewswireMay 23 17:51 ET

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncol

GlobeNewswireMay 23 09:00 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)

TipRanksMay 20 06:02 ET

Coherus Biosciences (CHRS) Gets a Hold From Maxim Group

TipRanksMay 18 13:25 ET

Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)

TipRanksMay 15 22:30 ET

Coherus BioSciences Is Maintained at Buy by Truist Securities

Coherus BioSciences Is Maintained at Buy by Truist Securities

Dow JonesMay 13 08:29 ET

Express News | Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7

BenzingaMay 13 08:19 ET

Express News | Coherus BioSciences Inc : Truist Securities Cuts Target Price to $7 From $8

ReutersMay 12 23:33 ET

Coherus BioSciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

There's been a notable change in appetite for Coherus BioSciences, Inc. (NASDAQ:CHRS) shares in the week since its quarterly report, with the stock down 16% to US$1.90. It looks to have been a d

Simply Wall StMay 12 09:11 ET

Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.

Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 10 15:47 ET

Express News | HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12

BenzingaMay 10 15:37 ET

Coherus BioSciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 559.34% HC Wainwright & Co. $11 → $12 Maintains Buy 03/20/2024 504.4% HC Wainwright & Co. $13 →

BenzingaMay 10 15:35 ET

Express News | Coherus BioSciences Shares Are Trading Lower After the Company Reported Better-than-expected Q1 Financial Results

BenzingaMay 10 12:28 ET